Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Does a combination of Arimidex and Zoladex make endometriomas shrink and how is the following IVF outcome

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometriosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Combined treatment with Arimidex and Zoladex before IVF

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Endometrioma(s)with a size of 20-70 mm, persisted for at least 3 cycles
* Couples with indication and wish for IVF/ICSI
* Age of women: 20-40 years
* Regular menstrual cycle within normal range (21-35 days)
* Body Mass Index (BMI): 18-30 kg/m2

Exclusion Criteria

* History with osteoporosis, liver-, kidney- or heart disease or thromboembolic disease
* Treatment of endometriosis with GnRH agonist during the last 3 month

Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kristine Lossl, medical doctor

Role: PRINCIPAL_INVESTIGATOR

The Fertility Clinic, Copenhagen University Hospital Rigshospitalet

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Fertility Clinic, Copenhagen University Hospital, Rigshospitalet

Copenhagen, Copenhagen East, Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

endo 220604

Identifier Type: -

Identifier Source: org_study_id